Sinovac remains unregistered and is not authorised by the Health Sciences Authority (HSA), and is to be provided only under the SAR framework. As such, it will not be covered under the Vaccine Injury Financial Assistance Programme (VIFAP) meant for the national vaccination programme.
Prof Mak noted that there still is some "outstanding data" on the vaccine that Sinovac has not provided to HSA, which is required to give "complete assurance" about its quality and safety profile. "We look forward, if data becomes available for us, then to (commence) this process of evaluation but unfortunately we're not able to do so."
